Antiviral Drug News and Research

RSS

Montefiore and Einstein evaluate a new drug combination to fight COVID-19

Montefiore Health System Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection.

26 May 2020

Antiviral drug can help accelerate recovery of COVID-19 patients, study shows

An international team of researchers led by Dr. Eleanor Fish, emerita scientist at the Toronto General Hospital Research Institute, University Health Network, and professor in the University of Toronto's Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.

15 May 2020

Study shows 19 out of 25 COVID-19 patients improved with convalescent plasma treatment

The country's first convalescent plasma transfusion trial results have been published and show 19 out of 25 patients improved with the treatment, and 11 were discharged from the hospital.

13 May 2020

UCI Health to initiate clinical trial of a drug to treat critically ill COVID-19 patients

UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.

13 May 2020

Passive immummization can offer instant, short-term fortification against infectious agents

The worldwide COVID-19 pandemic has infected more than 4 million people and killed close to 280,000.1 Finding a vaccine has become a global public health priority.

13 May 2020

Leica Microsystems Donate an Advanced Microscopy System to Charité’s Institute of Virology to Progress Covid-19 Research

Since the start of the current coronavirus outbreak, the Institute of Virology on Campus Charité Mitte, led by Director Prof. Dr. Christian Drosten, has been at the forefront of viral research into SARS-CoV-2, the virus that causes Covid-19.

From Leica Microsystems GmbH 12 May 2020

Most COVID-19 patients lose sense of smell by the third day, shows study

A University of Cincinnati researcher says a study of COVID-19 patients shows loss of the sense of smell is most likely to occur by the third day of infection with the novel virus. Most of these patients are also experiencing a loss of the sense of taste.

8 May 2020

Modified dialysis device treats COVID-19

As part of a randomized controlled trial, a team from Lawson Health Research Institute is the first in the world to treat a patient with COVID-19 using a modified dialysis device.

7 May 2020

Study discovers inhibition of SARS-CoV-2 entry priming protein by approved drug

The COVID-19 pandemic caused by the severe acute respiratory syndrome -coronavirus 2 (SARS-CoV-2) has spread to most of the world, causing millions of cases and hundreds of thousands of deaths. A new study published on the preprint server bioRxiv* shows that a protease inhibitor drug already approved by the Food and Drug Administration (FDA) could inhibit viral entry.

6 May 2020

SARS-CoV-2 genome shows mutation hotspots and type-specific distribution

Now, a new study published on the preprint server bioRxiv reports on a large scale analysis of SARS-CoV-2 genomes and reveals a clonal geo-distribution and rich genetic variations.

5 May 2020

UC San Diego receives $55 NIH grant to advance clinical and translational research

The Altman Clinical and Translational Research Institute at University of California San Diego has received a five-year, $54.7 million Clinical and Translational Science Award from the National Center for Advancing Translational Science, part of the National Institutes of Health.

4 May 2020

Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2

Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.

3 May 2020

Spike protein analysis from India's first SARS-CoV-2

A new study published on the preprint server bioRxiv analyzes viral spike protein sequences from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in West Bengal, India, comparing them with sequences from other Indian states and Wuhan, China.

30 Apr 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

GlobalData offers view on Gilead’s suspension of Covid-19 trials in China

Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus have been suspended due to lack of eligible patients;

From Gilead Sciences, Inc. 29 Apr 2020

UAB to join international effort to test drugs for COVID-19

The University of Alabama at Birmingham will join an international effort coordinated by Scripps Research to test drugs for COVID-19.

24 Apr 2020

Research looks at best ways to tackle coronavirus crisis

A new study published in the journal Frontiers in Microbiology in April 2020 discusses the most attractive approaches among the broad spectrum of experimental and theoretical strategies being worked on to counter the COVID-19 pandemic.

24 Apr 2020

Chinese scientists develop two novel compounds that inhibit SARS-CoV-2 main protease

A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a good drug candidate for further clinical studies.

23 Apr 2020

Genomic sequencing shows COVID-19 spread patterns

Throughout the spread of the virus, genomic sequencing has played a role in epidemiologic tracking of the viral strains carried all over the world. Such strains are traced back to their origin by their unique mutations and help to link remote infections.

22 Apr 2020

Scripps Research established international network to find antiviral compounds against COVID-19

With the COVID-19 pandemic continuing to spread around the globe, Scripps Research has quickly established an international network of collaborating scientific laboratories to leverage ReFRAME, the world's leading drug repurposing collection, to find antiviral compounds against the novel coronavirus.

22 Apr 2020